stockrow
Monday 9 November 2026
Export CGEN’s income statement to Excel — free account
Compugen Ltd.
CGENCompugen Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $72.8 million, up 161.1% from fiscal 2024.
- Revenue
- +107.0%
- EPS
- +12.5%
- Free cash flow
- −155.4%
Quarter to June 2026, against a year earlier
1.96
0.04
+2.08%
Follow CGEN
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 1 | — | 18 | — | 2 | 6 | 8 | 33 | 28 | 73 | 74 | +67.2% | 9 | 8 | 18 | (37.2%) | |
| Gross margin, % | 68.68 | 0.00 | 94.19 | 0.00 | 97.00 | 88.67 | 87.00 | 94.01 | 71.54 | 87.29 | 86.89 | +18.6 pt | ||||||
| EBT | (31) | (37) | (23) | (28) | (30) | (34) | (34) | (10) | (10) | 35 | 35 | n/m | ||||||
| EBT margin, % | (4,422.19) | 0.00 | (126.96) | 0.00 | (1,484.90) | (570.05) | (448.48) | (29.24) | (34.84) | 48.65 | 47.63 | +4,470.8 pt | ||||||
| Net income | (32) | (37) | (23) | (27) | (30) | (34) | (34) | (19) | (14) | 35 | 35 | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.01 | 0.00 | 0.32 | 0.00 | 0.03 | 0.07 | 0.09 | 0.38 | 0.31 | 0.78 | 0.78 | +56.3% | |||||
| Earnings | (0.62) | (0.72) | (0.41) | (0.43) | (0.37) | (0.41) | (0.39) | (0.21) | (0.16) | 0.38 | 0.38 | n/m | ||||||
| Cash flow | (0.39) | (0.60) | (0.24) | (0.44) | (0.36) | (0.27) | (0.39) | (0.41) | 0.55 | 0.34 | 0.43 | n/m | ||||||
| Capex | (0.05) | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | (0.01) | 0.00 | 0.00 | 0.00 | (0.01) | (26.2%) | ||||||
| Free cash flow | (0.44) | (0.61) | (0.24) | (0.43) | (0.36) | (0.27) | (0.40) | (0.41) | 0.55 | 0.34 | 0.42 | n/m | ||||||
| Book value | 1.25 | 0.57 | 0.67 | 0.60 | 1.51 | 1.27 | 0.90 | 0.75 | 0.61 | 1.10 | 0.94 | (1.4%) | ||||||
| Shares, m | 51 | 51 | 55 | 64 | 80 | 84 | 87 | 88 | 90 | 93 | 94 | +7.0% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 0.00 | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.14 | 5.16 | 0.5 | |||||
| P/S | 364.28 | — | 6.72 | — | 48.68 | 22.92 | 3.96 | 11.31 | 4.92 | 1.96 | 2.51 | 58.1 | ||||||
| P/B | 4.08 | — | 3.22 | — | 8.05 | 3.39 | 0.79 | 2.67 | 2.49 | 1.39 | 2.09 | 3.3 | ||||||
| EV/Sales | 277.86 | — | 4.16 | — | 42.39 | 15.46 | (1.44) | 8.01 | 1.21 | (0.04) | 0.81 | 43.5 | ||||||
| EV/FCF | (3.32) | — | (1.10) | — | (10.00) | (3.17) | 0.24 | (1.13) | 0.53 | (0.03) | 1.50 | (2.2) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (20) | (31) | (13) | (28) | (28) | (23) | (34) | (36) | 50 | 32 | 41 | n/m | |||||
| Capex | (3) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (1) | (21.2%) | ||||||
| Free cash flow | (22) | (31) | (13) | (28) | (28) | (23) | (35) | (36) | 49 | 31 | 40 | n/m | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 58 | 25 | 37 | 38 | 119 | 106 | 74 | 88 | 86 | 125 | 107 | +9.0% | |||||
| Net debt | (62) | (30) | (46) | (44) | (124) | (118) | (84) | (51) | (103) | (146) | (125) | +10.0% | ||||||
| Shareholders’ equity | 64 | 29 | 37 | 38 | 120 | 107 | 78 | 66 | 55 | 103 | 89 | +5.5% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (36.97) | (67.46) | (49.17) | (51.12) | (30.92) | (25.29) | (29.77) | (17.40) | (12.04) | 26.03 | 23.86 | +63.0 pt | |||||
| ROIC | (1,022.31) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (55.97) | 0.00 | 0.00 | 0.00 | +1,022.3 pt | ||||||
| ROE | (41.07) | (79.87) | (67.93) | (72.35) | (37.57) | (30.20) | (36.55) | (26.19) | (23.63) | 44.84 | 47.85 | +85.9 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 98 | 101 | 89 | 61 | 68 | 73 | 69 | 68 | 74 | 75 | — | (2.9%) | |||||
| Revenue/emp, $m | 0.01 | 0.00 | 0.20 | 0.00 | 0.03 | 0.08 | 0.11 | 0.49 | 0.38 | 0.97 | — | +72.3% | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026
Compugen Ltd. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| TRDA Entrada Therapeutics, Inc. | $191.5M | — (loss-making) | — (loss-making) | −43.93% (below 0%: shrinking) | n/m | −7.05% (below 0%: shrinking) | 100.00% | (4,606.52%) | Compare |
| PRQR ProQR Therapeutics N.V. | $190.5M | — (loss-making) | — (loss-making) | +135.03% (above 0%: growing) | n/m | −1.06% (below 0%: shrinking) | 100.00% | (100.72%) | Compare |
| RNA Atrium Therapeutics, Inc. | $185.8M | — (loss-making) | — (loss-making) | — | n/m | — | 100.00% | (752.93%) | Compare |
| CGEN Compugen Ltd. | $185.7M | 5.2× | — (loss-making) | +107.00% (above 0%: growing) | n/m | −155.42% (below 0%: shrinking) | (3.54%) | (339.62%) | |
| KROS Keros Therapeutics, Inc. | $183.7M | — (loss-making) | — (loss-making) | +120.22% (above 0%: growing) | n/m | +6.87% (above 0%: growing) | 100.00% | 32.04% | Compare |
| BCYC Bicycle Therapeutics PLC Sponsored ADR | $182.5M | — (loss-making) | — (loss-making) | +190.24% (above 0%: growing) | n/m | +43.48% (above 0%: growing) | 100.00% | (39.57%) | Compare |
| ACOG Alpha Cognition Inc. | $180.5M | — (loss-making) | — (loss-making) | +267.56% (above 0%: growing) | n/m | −109.25% (below 0%: shrinking) | 94.80% | (127.29%) | Compare |
| UPB Upstream Bio, Inc. | $176.9M | — (loss-making) | — (loss-making) | −17.50% (below 0%: shrinking) | n/m | +9.33% (above 0%: growing) | 100.00% | (5,480.98%) | Compare |
| BBOT BridgeBio Oncology Therapeutics, Inc | $163.6M | — (loss-making) | — | — | n/m | −88.78% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $183.1M | — | — | +127.63% | — | −1.06% | 100.00% | (114.00%) |